Warning Letter — Trinity HealthCare Supply, LLC dba altRx
The FDA issued a Warning Letter to Trinity HealthCare Supply, LLC (dba altRx) on June 8, 2026, through the Center for Drug Evaluation and Research (CDER).
This action affects Trinity HealthCare Supply, LLC, its subsidiary altRx, and regulatory and compliance departments responsible for drug distribution and marketing.
Issuance of a warning letter by CDER typically indicates that the FDA has identified significant violations of the Federal Food, Drug, and Cosmetic Act. This suggests that the company's products or marketing practices may involve unapproved new drugs or misbranded drug products, potentially leading to further enforcement actions such as seizures or injunctions if not remediated.
The recipient must conduct a comprehensive review of all product listings and marketing claims to ensure alignment with FDA pharmaceutical regulations. Legal and regulatory teams should prepare a formal response to the CDER addressing the specific violations cited in the warning letter within the standard 15-day window.
FDA Warning Letter issued to: Trinity HealthCare Supply, LLC dba altRx. 06/08/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/trinity-healthcare-supply-llc-dba-altrx-728236-06082026
Open in openFDA / FDA.gov